Latest Conference Articles

Horst explains the importance of addressing depression and anxiety in patients with IBD and steps clinicians can take to support their patients’ mental health.

A post hoc analysis of trial data reveals the effects of intraretinal fluid on best-corrected visual acuity in patients after port delivery system treatment for nAMD.

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

Subgroup analysis findings highlight duvakitug’s efficacy and tolerability across different levels of inflammation in ulcerative colitis.

Biomarker-informed molecular guidance led to greater achievement of disease control compared with standard “best care” for IBD anti-TNF therapy.

Gregory Cote, MD, reviews SHARP trial data suggesting ERCP with miES does not reduce acute pancreatitis risk in acute recurrent pancreatitis and pancreas divisum.

A post hoc analysis of data from the PULSAR trial indicates that patients with aflibercept 8 mg achieved disease activity control early and in high proportion.

Anthony Kerbage, MD, explains the heightened risk of repeat screening colonoscopy among patients with a primary language other than English.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

Fendrick describes patients’ desire for green screening options and reviews findings from a study comparing the environmental impact of screening tools.

Zhang describes the importance of multidisciplinary care for preventing alcohol relapse post-transplant, citing success from Mass General’s LIFT Clinic.

Gold explains misconceptions about who is affected by EoE and describes the importance of understanding the impact of SDoH in this patient population.

Fendrick describes the importance of follow-up colonoscopy after a positive result on a noninvasive test and factors influencing follow-up rates.

FibroX showed superior performance, interpretability, and potential cost savings relative to FIB-4, improving risk stratification and management in MASLD.

Pontecorvi describes the unique features of the EndoZip system and reviews findings from a study on its use for treating obesity-related comorbidities.

Compared with non-users, the cannabis use cohort showed significantly greater risks of acute pancreatitis flare pancreatic cancer, and all-cause mortality.

Feuerstadt explains recent advances in treating recurrent C diff and reviews new data on the safety and administration of fecal microbiota, live-jslm (Rebyota).

Long-term childhood outcomes were comparable in biologic-exposed and unexposed infants born to mothers with inflammatory bowel disease.

Shah explores the impact of hyperosmolarity on tear film post-cataract surgery, emphasizing the need for enhanced dry eye management strategies.

A new study highlights rapid relief and high satisfaction with PFHO for dry eye disease, showing significant symptom improvement within minutes.

In this interview, Christopher Bunick, MD, PhD, speaks on the elements of the RAD 2025 conference that he is most anticipating.

Trial data reveal phentolamine ophthalmic solution's potential to treat night vision disturbances post-keratorefractive surgery, addressing a critical unmet need.

Phentolamine ophthalmic solution significantly enhances outcomes post-dilation, rapidly returning visual symptoms to baseline levels.

Lifitegrast shows rapid and sustained relief for dry eye disease, with high satisfaction among providers and patients, according to recent findings.

Younger age and recurrent disease significantly increase the risk of pterygium progression, highlighting critical factors for ophthalmologists.

A study reveals Johnson & Johnson’s TECNIS Odyssey IOL offers excellent vision for presbyopia, with minimal dysphotopsia bothersomeness reported by patients.

BRIMOCHOL PF offers lasting near vision improvement for presbyopia, demonstrating robust efficacy and safety in a landmark Phase 3 study.

Long-term analysis confirms lifitegrast's safety for dry eye treatment, showing no new safety signals in nearly 800,000 patient treatment years.